Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Should l Buy ?
Source: Newsfilter
Bionomics Presentation Announcement: Bionomics Limited will present the results of its Phase 2 ATTUNE trial for BNC210, a treatment for post-traumatic stress disorder (PTSD), at the American College of Neuropsychopharmacology's annual meeting on December 8, 2024.
Company Overview: Bionomics is a clinical-stage biotechnology company focused on developing innovative treatments for central nervous system disorders, with BNC210 being its lead candidate for social anxiety disorder and PTSD.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
